Investments
156Portfolio Exits
24Funds
11About Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC with a focus on seed and early stage opportunities in biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. The firm has approximately $350 million under management in five venture capital funds. Hatteras is led by a seasoned team of entrepreneurs and operators and has a long and successful track record of seed and early stage investing and company formation.
Hatteras Venture Partners Headquarter Location
280 S. Mangum St. Suite 350
Durham, North Carolina, 27701,
United States
919-484-0730
Latest Hatteras Venture Partners News
Mar 11, 2022
Wildflower Health, a women’s health solutions company specializing in digital and value-based care has raised$26 million in new funding. The round was led by TT Capital Partners with participation from existing investors, including Providence Ventures, Health Enterprise Partners, Hatteras Venture Partners, and Echo Health Ventures. “Despite increased venture investments in women’s health, providers and payers have struggled to advance true value-based care…
Hatteras Venture Partners Investments
156 Investments
Hatteras Venture Partners has made 156 investments. Their latest investment was in Configo Health as part of their Seed VC on April 4, 2022.
Hatteras Venture Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
4/27/2022 | Seed VC | Configo Health | $2M | Yes | 2 | |
3/8/2022 | Series D | Wildflower Health | $26M | No | 9 | |
2/4/2022 | Series A | Huma.AI | $9.57M | Yes | 7 | |
1/7/2022 | Series B | |||||
12/2/2021 | Series A |
Date | 4/27/2022 | 3/8/2022 | 2/4/2022 | 1/7/2022 | 12/2/2021 |
|---|---|---|---|---|---|
Round | Seed VC | Series D | Series A | Series B | Series A |
Company | Configo Health | Wildflower Health | Huma.AI | ||
Amount | $2M | $26M | $9.57M | ||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 2 | 9 | 7 |
Hatteras Venture Partners Portfolio Exits
24 Portfolio Exits
Hatteras Venture Partners has 24 portfolio exits. Their latest portfolio exit was AN2 Therapeutics on March 25, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
3/25/2022 | IPO | 12 | |||
1/11/2022 | Acquired | 3 | |||
1/7/2022 | IPO | 7 | |||
Date | 3/25/2022 | 1/11/2022 | 1/7/2022 | ||
|---|---|---|---|---|---|
Exit | IPO | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 12 | 3 | 7 |
Hatteras Venture Partners Fund History
11 Fund Histories
Hatteras Venture Partners has 11 funds, including Hatteras Venture Partners VI.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
10/15/2020 | Hatteras Venture Partners VI | $137.3M | 4 | ||
1/23/2020 | Hatteras Evergreen Private Equity Fund | $27M | 1 | ||
2/28/2017 | Venture Capital Multiplier Fund | Co-Investment VC | Closed | $60M | 2 |
1/5/2017 | Hatteras Venture Partners V | ||||
1/7/2013 | Hatteras Venture Partners IV LP |
Closing Date | 10/15/2020 | 1/23/2020 | 2/28/2017 | 1/5/2017 | 1/7/2013 |
|---|---|---|---|---|---|
Fund | Hatteras Venture Partners VI | Hatteras Evergreen Private Equity Fund | Venture Capital Multiplier Fund | Hatteras Venture Partners V | Hatteras Venture Partners IV LP |
Fund Type | Co-Investment VC | ||||
Status | Closed | ||||
Amount | $137.3M | $27M | $60M | ||
Sources | 4 | 1 | 2 |
Hatteras Venture Partners Team
7 Team Members
Hatteras Venture Partners has 7 team members, including current General Partner, John Crumpler.
Name | Work History | Title | Status |
|---|---|---|---|
John Crumpler | Catalysta Ventures | General Partner | Current |
Michael Dial | Silicon Valley Bank, and National Institute of Environmental Health Sciences | General Partner | Current |
Robert A. Ingram | General Partner | Current | |
Kenneth B. Lee | General Partner | Current | |
Douglas W. Reed | Vector Fund Management, Geltex Pharmaceuticals, Nps Pharmaceuticals, Yale University, and University of Washington | General Partner | Current |
Name | John Crumpler | Michael Dial | Robert A. Ingram | Kenneth B. Lee | Douglas W. Reed |
|---|---|---|---|---|---|
Work History | Catalysta Ventures | Silicon Valley Bank, and National Institute of Environmental Health Sciences | Vector Fund Management, Geltex Pharmaceuticals, Nps Pharmaceuticals, Yale University, and University of Washington | ||
Title | General Partner | General Partner | General Partner | General Partner | General Partner |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.